MxA mRNA decrease preceding NAb detection in IFNβ‐treated MS patients

BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNβ) are at risk of a declining response to treatment because of the production of IFNβ‐neutralizing antibodies (NAbs). The expression of Myxovirus resistance protein A (MxA) mRNA is regarded as a marker of IFNβ bioactivity....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Brain Behav
Hlavní autoři: Libertinova, Jana, Meluzinova, Eva, Matoska, Vaclav, Zajac, Miroslav, Kovarova, Ivana, Havrdova, Eva, Horakova, Dana, Tomek, Ales, Marusic, Petr, Bojar, Martin
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346526/
https://ncbi.nlm.nih.gov/pubmed/28293479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.644
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky